Concord Drugs Adjusts Evaluation Score Amid Mixed Technical Indicators and Performance Challenges
Concord Drugs, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation score, reflecting a shift in technical trends. Despite notable annual returns and an attractive valuation, the company faces challenges with declining operating profits and constrained debt management.
Concord Drugs, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a mildly bullish stance to a bullish outlook. The technical indicators present a mixed picture; while the MACD shows bullish signals on both weekly and monthly bases, the RSI indicates bearish conditions on a weekly scale, with no signal on a monthly basis. The Bollinger Bands and moving averages suggest a bullish trend, particularly on a daily basis.
In terms of performance, Concord Drugs has demonstrated notable returns, with a 45.81% increase over the past year, significantly outperforming the BSE500 index. However, the company has experienced a decline in operating profits over the last five years, with a CAGR of -8.82%. Additionally, the company's ability to manage debt appears constrained, as indicated by a low EBIT to Interest ratio of 1.43.
Despite these challenges, Concord Drugs maintains an attractive valuation, trading at a discount compared to its peers. The stock's recent performance and technical adjustments highlight its complex position within the market.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
